Navigating the risks of using concomitant antipeptic agents in light of osteoporotic concerns

참고문헌 (10)

1. Shin GY, "Use of proton pump inhibitors vs histamine 2 receptor antagonists for the risk of gastric cancer : population-based cohort study", Am J Gastroenterol, 116, pp.1211~1219 (2021)
2. Freedberg DE, "The risks and benefits of long-term use of proton pump inhibitors : expert review and best practice advice from the American Gastroenterological Association", Gastroenterology, 152, pp.706~715 (2017)
3. Lo CH, "Association of proton pump inhibitor use with all-cause and cause-specific mortality", Gastroenterology, 163, pp.852~861 (2022)
4. Ghosh G, "Reported proton pump inhibitor side effects : what are physician and patient perspectives and behaviour patterns?", Aliment Pharmacol Ther, 51, pp.121~128 (2020)
5. Park JH, "Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures : a nested case-control study of more than 350, 000 Korean patients with GERD and peptic ulcer disease", BMC Geriatr, 20, pp.407~ (2020)
6. Liu J, "Proton pump inhibitors therapy and risk of bone diseases : an update meta-analysis", Life Sci, 218, pp.213~223 (2019)
7. Li J, "Acid-suppressive drugs and risk of fracture in children and young adults : a meta-analysis of observational studies", Front Pharmacol, 12, pp.712939~ (2021)
8. Kim JM, "Osteoblast-osteoclast communication and bone homeostasis", Cells, 9, pp.2073~ (2020)
9. Yang YX, "Long-term proton pump inhibitor therapy and risk of hip fracture", JAMA, 296, pp.2947~2953 (2006)
10. Oh DJ, "The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture : a nationwide case-control study", Korean J Intern Med (2024)[DOI]